CLINICAL_TRIALS trial_result · 2016-05-13

Clinical Trial Update: A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease [Phase 2]

A 36-week safety extension study of ELND005 for agitation and aggression in Alzheimer's disease was terminated; results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: OPKO Health, Inc. | Conditions: Alzheimer's Disease | Phase 2 | Status: TERMINATED | Results posted: 2016-05-13